Allergic conjunctivitis is an increasingly prevalent allergic reaction having clinical gravity similar to asthma and allergic rhinitis. Currently around 40% of global population is suffering from allergic conjunctivitis. After obtaining approval and clearance from the Institutional ethics committee, the patients diagnosed with allergic conjunctivitis and those fulfilling the inclusion criteria were enrolled for the study after obtaining informed consent. A full medical and ocular history was taken on Case record form with follow up chart. The differences in mean age and gender distribution were not statistically significant (p value for Alcaftadine was 0.17 and Bepotastine was 0.502). The data reveals that most of the participants in the Alcaftadine group (n=37, 69.81%) and in the Bepotastine group, (n=35, 66.04%) did not have any similar episodes of allergic conjunctivitis in the past while 16 participants (30.19%) in the Alcaftadine group and 18 participants (33.96%) in Bepotastine group had similar episodes in the past.